00:00:00:00

On-demand WEBINAR

Share the Science webinar: Umbilical cord blood-derived novel cellular therapies for treatment of lymphomas


Presented by WellSky and Save the Cord Foundation

Join us for an exclusive Share the Science webinar featuring Dr. Yago Nieto from MD Anderson Cancer Center to learn about the mechanism of NK cells, an analysis of studies of donor NK cell therapy with a focus on those studies using banked cord blood as source, and review of the future lines of progress

Register Now

About the speaker

Dr. Yago L. Nieto, MD, PhD
Professor of Medicine, MD Anderson Cancer Center

Expert with 25+ years of experience in stem cell transplantation and cellular therapy.

Dr. Yago Nieto, MD, PhD, is a Professor of Medicine at The University of Texas MD Anderson Cancer Center in the Department of Stem Cell Transplantation and Cellular Therapy. He is a stem-cell transplant specialist with 25 years of experience in the field. His research focus is the development of novel chemotherapy regimens for use in autologous and allogeneic transplantation for lymphomas and the introduction of novel therapeutics. Dr. Nieto is the PI of numerous investigator-initiated clinical trials. He serves as the Co-Chairman of the Myeloma Working Group & Solid Tumor Working Group for the Center for International Blood and Marrow Transplant Research (CIBMTR). Dr. Nieto has received numerous awards throughout his career including America’s Top Physician and Mentor of the Year Award at MD Anderson Cancer Center.

What you'll learn

Natural killer (NK) cells are key elements of the immune system, and they play a crucial role in eradicating cells that have become malignant or infected with a virus. Cord blood is an important source of NK cells; however, they require a complex process of activation, manufacturing, and expansion in the lab prior to infusion to patients with cancer. Dr. Nieto is part of a group at MD Anderson Cancer Center that has developed off-the-shelf, frozen, cord blood-derived NK cells that have been tested in a variety of cancers with encouraging results. During the webinar, Dr. Nieto will:


1

Discuss the mechanism of action of natural killer (NK) cells and their source for treatment of cancer

2

Analyze the study results of donor NK cell therapy, focusing on those studies using banked cord blood as source

3

Review future lines of progress

Special feature

Includes a live Q&A facilitated by Charis Ober, Founder and Executive Director of Save the Cord Foundation. Come with questions and engage directly with leading experts.

About Save the Cord Foundation

 
Share the Science is a free webinar series designed to bring you powerful presentations by the top experts in cellular therapy. Generously supported by WellSky and Save the Cord Foundation, Share the Science webinars connect you to the world's most innovative and influential scientists, clinical researchers, and experts as they discuss the latest breakthroughs and most promising developments in cellular therapy. Learn more about Save the Cord Foundation.

Register for the on-demand webinar!


Block 1
editable text
Block 2 Top
editable text
Block 2 Bottom
editable text
grows to fill column
Block 3 Top
editable text
Block 3 Bottom
editable text
grows to fill column
Block 4
editable text
Block 1
editable text
Block 2 Top
editable text
Block 2 Bottom
editable text
grows to fill column
Block 3 Top
editable text
Block 3 Bottom
editable text
grows to fill column
Block 4
editable text

About WellSky

WellSky® is one of America’s largest and most innovative healthcare technology companies, leading the movement for intelligent, coordinated care. In today’s value-based care environment, WellSky connects providers, payers, health systems, life sciences companies, and community organizations through AI-powered software, analytics, and services. Our solutions help organizations scale smarter, collaborate more effectively, and unlock data-driven insights. The result is better alignment across all dimensions of clinical and social care — supporting better outcomes and lower costs.

WellSky serves more than 20,000 client sites — including the largest hospital systems, blood banks, cell therapy labs, home health and hospice franchises, post-acute providers, government agencies, and human services organizations. With more than 40 years of industry expertise further amplified by AI, WellSky anticipates clients’ needs and innovates relentlessly to shape the future of coordinated care. For more information, visit wellsky.com.